<DOC>
	<DOCNO>NCT02718677</DOCNO>
	<brief_summary>This NIS aim evaluate efficacy safety ReFacto AF Standard Prophylaxis Treatment child severe hemophilia A Romania</brief_summary>
	<brief_title>Efficacy &amp; Safety REFACTO AF Prophylaxis Treatment</brief_title>
	<detailed_description>Patients receive standard prophylaxis treatment ReFacto AF determine inclusion criterion include study . During observational study , patient diagnose severe hemophilia A , start continue prophylaxis ReFacto AF per local standard clinical care , observe 12 month . Patients receive prophylaxis another FVIII product schedule switch ReFacto AF prophylaxis also enrol . Physician decision initiate continue ReFacto AF prophylaxis therapy independent precede subject ' inclusion study . Also physician decision switch prophylaxis another FVIII product ReFacto AF independent precede subject ' inclusion study . Detailed information hemophilia A history previous hemophilia treatment collect Baseline . The number bleeding treatment , status joint quality life assess 3 , 6 , 9 12 month ReFacto AF prophylaxis initiation . ReFacto AF dose treatment duration discretion investigator accordance local clinical practice local labeling . All clinical laboratory assessment study conduct per current medical practice management hemophilia A without study related procedure .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Male subject severe hemophilia A ( FVIII : C &lt; 1 % ) 2 . Age 1 18 year 3 . Previously untreated patient ( PUPs ) previously treat patient ( PTPs ) factor VIII 4 . No previous history FVIII inhibitor 5 . Legally authorized representative pediatric patient agree provide write informed consent form 6 . Patients scheduled hematologist initiate prophylaxis ReFacto AF continue previously initiate prophylaxis ReFacto AF , include patient switch prophylaxis another FVIII product ReFacto AF . 1 . Subject know hypersensitivity active substance excipients . 2 . Subject know allergic reaction hamster proteins 3 . Presence bleed disorder addition hemophilia A . 4 . Treatment investigational agent device within past 30 day . 5 . Any contraindication accord Summary Product Characteristics 6 . Unsuitable participate study reason assess investigator</criteria>
	<gender>Male</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>